

Melani Anita Solomon

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5556001/publications.pdf>

Version: 2024-02-01

22
papers

432
citations

759233

12
h-index

752698

20
g-index

22
all docs

22
docs citations

22
times ranked

802
citing authors

#	ARTICLE	IF	CITATIONS
1	Comparison between Nanoparticle Encapsulation and Surface Loading for Lysosomal Enzyme Replacement Therapy. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4034.	4.1	7
2	A method to improve quantitative radiotracing-based analysis of the in vivo biodistribution of drug carriers. <i>Bioengineering and Translational Medicine</i> , 2021, 6, e10208.	7.1	4
3	Intracellular Delivery of Active Proteins by Polyphosphazene Polymers. <i>Pharmaceutics</i> , 2021, 13, 249.	4.5	9
4	Intertwined mechanisms define transport of anti-ICAM nanocarriers across the endothelium and brain delivery of a therapeutic enzyme. <i>Journal of Controlled Release</i> , 2020, 324, 181-193.	9.9	14
5	α -Tocopherol Effect on Endocytosis and Its Combination with Enzyme Replacement Therapy for Lysosomal Disorders: A New Type of Drug Interaction?. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2019, 370, 823-833.	2.5	6
6	Nanomechanical Analysis of Extracellular Matrix and Cells in Multicellular Spheroids. <i>Cellular and Molecular Bioengineering</i> , 2019, 12, 203-214.	2.1	19
7	Unprecedentedly high targeting specificity toward lung ICAM-1 using 3DNA nanocarriers. <i>Journal of Controlled Release</i> , 2019, 305, 41-49.	9.9	19
8	Dynamic and Depth Dependent Nanomechanical Properties of Dorsal Ruffles in Live Cells and Biopolymeric Hydrogels. <i>Journal of Nanoscience and Nanotechnology</i> , 2018, 18, 1557-1567.	0.9	2
9	Lysosomal enzyme replacement therapies: Historical development, clinical outcomes, and future perspectives. <i>Advanced Drug Delivery Reviews</i> , 2017, 118, 109-134.	13.7	107
10	Enhanced Delivery and Effects of Acid Sphingomyelinase by ICAM-1-Targeted Nanocarriers in Type B Niemann-Pick Disease Mice. <i>Molecular Therapy</i> , 2017, 25, 1686-1696.	8.2	27
11	Identification of psychosine-reducing small molecule agents for Krabbe disease. <i>Molecular Genetics and Metabolism</i> , 2017, 120, S90.	1.1	0
12	Co-coating of receptor-targeted drug nanocarriers with anti-phagocytic moieties enhances specific tissue uptake versus non-specific phagocytic clearance. <i>Biomaterials</i> , 2017, 147, 14-25.	11.4	26
13	Determination of the Subcellular Distribution of Liposomes Using Confocal Microscopy. <i>Methods in Molecular Biology</i> , 2017, 1522, 119-130.	0.9	2
14	Cell-based high-throughput screening identifies galactocerebrosidase enhancers as potential small-molecule therapies for Krabbe's disease. <i>Journal of Neuroscience Research</i> , 2016, 94, 1231-1245.	2.9	2
15	Development of an in vitro tumor spheroid culture model amenable to high-throughput testing of potential anticancer nanotherapeutics. <i>Journal of Liposome Research</i> , 2016, 26, 246-260.	3.3	25
16	Screen and identification of small molecules therapies to reduce elevated psychosine levels in globoid-cell leukodystrophy. <i>Molecular Genetics and Metabolism</i> , 2016, 117, S76-S77.	1.1	0
17	A Comparative Study on the Alterations of Endocytic Pathways in Multiple Lysosomal Storage Disorders. <i>Molecular Pharmaceutics</i> , 2016, 13, 357-368.	4.6	36
18	Hydrophobized triphenyl phosphonium derivatives for the preparation of mitochondriotropic liposomes: choice of hydrophobic anchor influences cytotoxicity but not mitochondriotropic effect. <i>Journal of Liposome Research</i> , 2016, 26, 21-27.	3.3	17

#	ARTICLE	IF	CITATIONS
19	Early axonal loss accompanied by impaired endocytosis, abnormal axonal transport, and decreased microtubule stability occur in the model of Krabbe's disease. <i>Neurobiology of Disease</i> , 2014, 66, 92-103.	4.4	55
20	In Vitro assessment of the utility of stearyl triphenyl phosphonium modified liposomes in overcoming the resistance of ovarian carcinoma Ovar-3 cells to paclitaxel. <i>Mitochondrion</i> , 2013, 13, 464-472.	3.4	32
21	Recent progress in the therapeutic applications of nanotechnology. <i>Current Opinion in Pediatrics</i> , 2011, 23, 215-220.	2.0	18
22	Approaches to Achieving Sub-cellular Targeting of Bioactives Using Pharmaceutical Nanocarriers. <i>Fundamental Biomedical Technologies</i> , 2011, , 57-72.	0.2	5